FLT4 antibody

Catalog No. ABIN2665454

Product Details anti-FLT4 Antibody

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This FLT4 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography.

Clone: 9D9F9

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for FLT4

Target: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Alternative Name: VEGFR-3 (FLT4 Products)

Synonyms: FLT41 antibody, LMPH1A antibody, PCL antibody, VEGFR3 antibody, AI323512 antibody, Chy antibody, Flt-4 antibody, VEGFR-3 antibody, Vegfr3 antibody, cb1059 antibody, fms related tyrosine kinase 4 antibody, FMS-like tyrosine kinase 4 antibody, fms-related tyrosine kinase 4 antibody, FLT4 antibody, Flt4 antibody, flt4 antibody

Background: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1-D7), a single transmembrane, helix, and a cytoplasmic region with tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides that remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system. Aberrant activation or expression of VEGFR and their ligands has been implicated in tumor angiogenesis, coronary artery disease, diabetic blindness, and other diseases.

Pathways: RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling